PharmaSonics Inc.

interest in vulnerable plaque is erupting. Device companies have taken the lead, but as biologic solution emerge, will that lead last? The second of a two-part series. by David Cassak As we noted last

The big news out of this year's TCT meeting in September wasn't really news at all. The final results of the SIRIUS clinical trial, assessing restenosis rates and other clinical measures of the siroli

They're forever blowing up bubbles 1635 East 18th Street Tucson, AZ 85719 Phone: (520) 770-1259 Fax: (520) 791-2437 Web Site: www.imarx.com Contact: Nina Ossanna, PhD, Senior Director, Busines

Solving the problem of post-revascularization restenosis gave lots of start-ups a reason to be. Will stunning early results on drug-eluting stents take it away? by Mary Stuart Innovative device compan